ReviewJournal of cardiovascular development and disease2026
Biomarkers of Cardiovascular Stress: A Historical Review.
Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Internal and external stress exerted by forces such as oxidative, xenobiotic, radiant, ischemic, mechanical, metabolic, neurohormonal, infectious, immunoinflammatory, emotional and psychological increases the risk of cardiovascular morbidity and mortality. Initiation and propagation of the explosive self-amplifying chain reaction of lipid peroxidation chain reaction (LPO) generates atherogenic and inflammatory toxic reactive oxygen species that cause cardiovascular tissue lesion that are the ultimate determinants of cardiovascular disease risk (CVD-R). Because the LPO toxins, cellular stress sensors and defenses, inter- and intracellular signaling, and pathogenic lesions are closely similar among these stressors, simultaneous exposure to multiple stresses can amplify LPO to accelerate accumulation of pathogenic lesions synergistically. Numerous blood tests measure LPO-derived toxins, stress-responsive metabolism and cytokines, which are used clinically as surrogate biomarkers of CVD-R. They can predict population risks quite well, but prediction of individual patient CVD-R using multiplex biomarker panels is hampered by lack of true independence between biomarkers, lack of understanding of their relative hierarchy in disease etiology or progression, and interference from comorbid diseases or acute-phase reactions. We present this historical review of landmark studies that led to the current clinical paradigms of CVD-R prediction to provide mechanistic and clinical context that will aid the development of integrated etiological biomarkers that reflect the multiple types of stress that promote CVD-R.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.